2025-04-29 15:41Financial Performance - Q1 2025 revenue increased by 210% year-over-year, reaching RMB 965 billion[13] - Adjusted non-IFRS net profit increased by 400% year-over-year, reaching RMB 268 billion[13] - Backlog for continuing operations increased by 471% year-over-year, reaching RMB 5233 billion[13] - Q1 2025 operating cash flow increased by 418% year-over-year, reaching RMB 303 billion[42] Segment Performance - WuXi Chemistry Q1 revenue increased by 329% year-over-year, reaching RMB 739 billion[19, 22] - TIDES revenue within WuXi Chemistry increased by 1876% year-over-year, reaching RMB 224 billion[19, 22] - WuXi Testing lab testing services revenue decreased by 49% year-over-year, reaching RMB 088 billion[26, 29] - WuXi Biology Q1 revenue increased by 82% year-over-year, reaching RMB 061 billion[30, 32] Regional Revenue - US revenue contribution is 66%, with RMB 638 billion, a 284% increase[16] - Europe revenue contribution is 13%, with RMB 130 billion, a 262% increase[16] - China revenue contribution is 16%, with RMB 153 billion, a 13% decrease[16] - Japan, Korea & Others revenue contribution is 5%, with RMB 045 billion, a 30% increase[16]